NecstGen will provide process development, cGMP manufacturing services up to 200 L, and cleanroom rental
Cytiva, a global life sciences specialist, and NecstGen, aim to accelerate the development of new cell and gene therapies globally via a strategic collaboration.
Cytiva will provide its technologies, services, and solutions to NecstGen, and both organisations will share their knowledge, expertise, and learnings as research programmes are translated into next-generation therapies.
Catarina Flyborg, VP of Cell and Gene Therapy at Cytiva, said: "Cell and gene therapies are transformative medicines and accelerating their development requires harnessing the power of the industry. By sharing our expertise and providing NecstGen with access to our team of specialists, Cytiva will play a critical role in taking translational research from the laboratory to the bedside."
Established in 2020, NecstGen is a non-profit contract development and manufacturing organisation (CDMO) specialising in cell and gene therapies in the Netherlands. It brings the development, production, QC, QA, and QP functions together in a new 4,000 sqm facility in Leiden Bio Science Park, the largest bio-cluster in the Netherlands. The new facility will serve all organisations worldwide, particularly academic and small/large industry enterprises who want to bring their research to the clinical stage.
NecstGen will provide process development, cGMP manufacturing services up to 200 L, and cleanroom rental.
Paul Bilars, CEO, NecstGen, said: "Our partnership with Cytiva will provide us with the flexible and scalable solutions needed by pioneers in the field of cell and gene therapy. Working together, we will accelerate the development of future therapies, bringing these to patients faster."
During the first half of 2021, there were 1,328 regenerative medicine trials underway globally sponsored by non-industry groups such as academic centres and government entities. Small and mid-size enterprises and academic centres play an important role in the development of novel cell and gene therapies. NecstGen addresses the needs of these early-phase therapy developers to help them bring new therapies to patients.